Skip Navigation


NDT Advance Access originally published online on October 7, 2008
Nephrology Dialysis Transplantation 2009 24(1):321-324; doi:10.1093/ndt/gfn538
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/1/321    most recent
gfn538v2
gfn538v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Malycha, F.
Right arrow Articles by Eitner, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malycha, F.
Right arrow Articles by Eitner, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients

Friederike Malycha1,2, Thomas Eggermann2, Mihail Hristov3, Francesco Paolo Schena4, Peter R. Mertens1, Klaus Zerres2, Jürgen Floege1 and Frank Eitner1

1 Division of Nephrology and Immunology 2 Department of Human Genetics 3 Institute for Molecular Cardiovascular Research, 1-3 Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany 4 Division of Nephrology, Bari, Italy

Frank Eitner, Universitätsklinikum Aachen, Medizinische Klinik II (Nephrologie und Immunologie), Pauwelsstr 30, 52074 Aachen, Germany. Tel: +49-241-8089-532; Fax: +49-241-8082-446; E-mail: feitner{at}ukaachen.de



  Abstract

Background. Altered IgA1 galactosylation is involved in the pathogenesis of IgA nephropathy (IgAN). The galactosyltransferase core-1 beta3-galactosyltransferase-1 (C1GALT1) and its chaperone cosmc are specifically required for O-galactosylation of the IgA1 hinge region. Mutations in the cosmc gene result in a secondary loss of function of C1GALT1 with subsequent undergalactosylation of glycoproteins. Mosaic mutations of cosmc have been shown to result in autoimmune disease. We hypothesized that cosmc mutations might contribute to the altered IgA1 galactosylation in IgAN patients.

Methods. We studied cosmc gene sequences in genomic DNA obtained from male patients with biopsy-proven sporadic (n = 33) and familial IgAN (n = 6 patients from different families). To account for a potential mosaicism we sequenced cosmc in 10 different peripheral blood mononuclear cell DNA clones of every patient. To specifically assess potential mosaic mutations in IgA-producing cells, cosmc mutations were also analysed in DNA isolated from CD20+ B-lymphocytes from three male IgAN patients.

Results. Despite our extensive genomic analysis, the data revealed no functionally relevant cosmc gene variants in sporadic or familial IgAN cases. A cosmc gene polymorphism, rs17261572, was identified in these IgAN patients in a similar frequency as previously reported in healthy adults. A functional consequence of this polymorphism has not yet been determined.

Conclusion. Although decreased C1GALT1 activity has been implicated in the IgAN pathogenesis and cosmc chaperone mutations can cause autoimmune disease, our data provide no evidence for a relevant role of cosmc gene mutations in European patients with sporadic or familial IgAN.

Keywords: chaperone; cosmc; galactosylation; IgA nephropathy; mutation

Received for publication: 8. 5.08
Accepted in revised form: 2. 9.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
R. Coppo and J. Feehally
Is progression of IgA nephropathy conditioned by genes regulating atherosclerotic damage?
Nephrol. Dial. Transplant., October 6, 2009; (2009) gfp524v1.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.